|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FHOD1 |
Gene summary for FHOD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FHOD1 | Gene ID | 29109 |
| Gene name | formin homology 2 domain containing 1 | |
| Gene Alias | FHOS | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A068F7M9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29109 | FHOD1 | LZE24T | Human | Esophagus | ESCC | 8.16e-04 | 5.29e-02 | 0.0596 |
| 29109 | FHOD1 | P1T-E | Human | Esophagus | ESCC | 3.08e-05 | 2.36e-01 | 0.0875 |
| 29109 | FHOD1 | P4T-E | Human | Esophagus | ESCC | 1.31e-10 | 1.33e-01 | 0.1323 |
| 29109 | FHOD1 | P5T-E | Human | Esophagus | ESCC | 1.48e-04 | 1.61e-01 | 0.1327 |
| 29109 | FHOD1 | P8T-E | Human | Esophagus | ESCC | 1.67e-02 | 7.31e-02 | 0.0889 |
| 29109 | FHOD1 | P11T-E | Human | Esophagus | ESCC | 3.94e-16 | 4.04e-01 | 0.1426 |
| 29109 | FHOD1 | P12T-E | Human | Esophagus | ESCC | 6.79e-07 | 1.13e-01 | 0.1122 |
| 29109 | FHOD1 | P15T-E | Human | Esophagus | ESCC | 9.61e-10 | 1.11e-01 | 0.1149 |
| 29109 | FHOD1 | P17T-E | Human | Esophagus | ESCC | 1.93e-03 | 2.61e-01 | 0.1278 |
| 29109 | FHOD1 | P19T-E | Human | Esophagus | ESCC | 1.02e-02 | 3.52e-01 | 0.1662 |
| 29109 | FHOD1 | P21T-E | Human | Esophagus | ESCC | 1.07e-09 | 2.11e-01 | 0.1617 |
| 29109 | FHOD1 | P23T-E | Human | Esophagus | ESCC | 3.63e-10 | 2.66e-01 | 0.108 |
| 29109 | FHOD1 | P24T-E | Human | Esophagus | ESCC | 4.43e-05 | 1.74e-01 | 0.1287 |
| 29109 | FHOD1 | P27T-E | Human | Esophagus | ESCC | 6.25e-12 | 1.04e-01 | 0.1055 |
| 29109 | FHOD1 | P28T-E | Human | Esophagus | ESCC | 4.58e-09 | 1.81e-01 | 0.1149 |
| 29109 | FHOD1 | P30T-E | Human | Esophagus | ESCC | 1.17e-09 | 1.78e-01 | 0.137 |
| 29109 | FHOD1 | P31T-E | Human | Esophagus | ESCC | 2.91e-07 | 1.89e-01 | 0.1251 |
| 29109 | FHOD1 | P32T-E | Human | Esophagus | ESCC | 3.87e-16 | 3.48e-01 | 0.1666 |
| 29109 | FHOD1 | P36T-E | Human | Esophagus | ESCC | 2.35e-02 | 1.04e-01 | 0.1187 |
| 29109 | FHOD1 | P37T-E | Human | Esophagus | ESCC | 3.96e-13 | 2.23e-01 | 0.1371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:011005327 | Esophagus | ESCC | regulation of actin filament organization | 166/8552 | 278/18723 | 1.54e-06 | 1.85e-05 | 166 |
| GO:00618428 | Esophagus | ESCC | microtubule organizing center localization | 28/8552 | 33/18723 | 3.80e-06 | 4.12e-05 | 28 |
| GO:005101727 | Esophagus | ESCC | actin filament bundle assembly | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:00516428 | Esophagus | ESCC | centrosome localization | 27/8552 | 32/18723 | 7.10e-06 | 7.12e-05 | 27 |
| GO:006157227 | Esophagus | ESCC | actin filament bundle organization | 101/8552 | 161/18723 | 9.22e-06 | 8.82e-05 | 101 |
| GO:003086517 | Esophagus | ESCC | cortical cytoskeleton organization | 44/8552 | 61/18723 | 2.50e-05 | 2.13e-04 | 44 |
| GO:003003820 | Esophagus | ESCC | contractile actin filament bundle assembly | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
| GO:004314920 | Esophagus | ESCC | stress fiber assembly | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
| GO:003223120 | Esophagus | ESCC | regulation of actin filament bundle assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
| GO:003223319 | Esophagus | ESCC | positive regulation of actin filament bundle assembly | 41/8552 | 63/18723 | 1.48e-03 | 6.99e-03 | 41 |
| GO:003086610 | Esophagus | ESCC | cortical actin cytoskeleton organization | 28/8552 | 40/18723 | 1.61e-03 | 7.50e-03 | 28 |
| GO:005149225 | Esophagus | ESCC | regulation of stress fiber assembly | 56/8552 | 91/18723 | 1.66e-03 | 7.68e-03 | 56 |
| GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0513230 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FHOD1 | SNV | Missense_Mutation | c.16N>T | p.Asp6Tyr | p.D6Y | Q9Y613 | protein_coding | deleterious_low_confidence(0) | benign(0.299) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| FHOD1 | SNV | Missense_Mutation | rs542514076 | c.2479G>T | p.Val827Leu | p.V827L | Q9Y613 | protein_coding | deleterious(0.03) | benign(0.173) | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FHOD1 | SNV | Missense_Mutation | c.3426N>C | p.Leu1142Phe | p.L1142F | Q9Y613 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FHOD1 | SNV | Missense_Mutation | novel | c.1192N>A | p.Ala398Thr | p.A398T | Q9Y613 | protein_coding | tolerated(0.42) | benign(0) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
| FHOD1 | SNV | Missense_Mutation | rs542514076 | c.2479N>T | p.Val827Leu | p.V827L | Q9Y613 | protein_coding | deleterious(0.03) | benign(0.173) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| FHOD1 | SNV | Missense_Mutation | rs542514076 | c.2479N>T | p.Val827Leu | p.V827L | Q9Y613 | protein_coding | deleterious(0.03) | benign(0.173) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FHOD1 | SNV | Missense_Mutation | c.1587C>G | p.Ile529Met | p.I529M | Q9Y613 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| FHOD1 | SNV | Missense_Mutation | c.2314N>T | p.Ala772Ser | p.A772S | Q9Y613 | protein_coding | tolerated(1) | benign(0.262) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FHOD1 | deletion | Frame_Shift_Del | novel | c.2461delC | p.Leu821TrpfsTer5 | p.L821Wfs*5 | Q9Y613 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FHOD1 | SNV | Missense_Mutation | novel | c.1610C>A | p.Pro537His | p.P537H | Q9Y613 | protein_coding | deleterious(0.02) | benign(0.401) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |